Protection against vaginal SIV transmission with microencapsulated vaccine.
about
Challenges in mucosal HIV vaccine development: lessons from non-human primate modelsPlague Vaccine Development: Current Research and Future TrendsCurrent views on the potential for development of a HIV vaccine.Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.Mucosal immune system of the human genital tract.The effect of route of immunization on mucosal immunity and protection.Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccinesFactors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virusNasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretionsEffective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virionsModulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvantsNasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodesSingle-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.Application of nanotechnologies for improved immune response against infectious diseases in the developing worldCross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.Increased macrophage infection upon subcutaneous inoculation of rhesus macaques with simian immunodeficiency virus-loaded dendritic cells or T cells but not with cell-free virus.Vaccine adjuvants: current state and future trends.Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccinationEarly preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.Preventing sexual transmission of HSV and HIV: the challenge for active and passive immunization of mucosal surfaces.Microparticles as vaccine adjuvants and delivery systems.Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation GroupAdjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheresOrally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit.Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant womenIntranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.Timed appearance of lymphocytic choriomeningitis virus after gastric inoculation of miceMacaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusMucosal AIDS vaccines: current status and future directions.Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangMurine infection with lymphocytic choriomeningitis virus following gastric inoculation.Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entryAn adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challengeMucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
P2860
Q27022152-122E424D-317F-498F-9EEE-A24F9423C5B4Q28066875-448DA2BD-1A34-4BEF-96C9-9005173B8088Q30397595-D625324F-3910-4CB7-8506-14426573F0CEQ32157115-4789E8D8-DAF1-4FC6-914D-2FF9993AD288Q33547159-E762138E-10AB-4622-B851-D485B3FCE501Q33547166-76A313BC-12A7-4564-9C44-A8C54409CC08Q33644522-F4779DDB-1B1A-4E27-B2C7-D229814F8E39Q33649657-C524C726-F525-4039-92B7-4A4F896AD8FEQ33760450-98A07454-D012-4C95-BF6A-D440445DB513Q33782096-03FB4623-7361-4609-88C2-481D437992E4Q33784891-2C42FE5C-6F4B-4009-827F-E68DF464181FQ33787271-AF71CC99-173F-4E13-BBCC-DDBFDD534650Q33801810-0EF3F843-7939-49B0-A26F-14C75CDE67B0Q33822614-4B673061-A233-44C8-8042-0861A301C6FCQ33868005-00D030C1-09BA-4477-8B22-C8ACE8DF01C2Q33877194-B7412CDE-7699-4BD7-A11A-B0B64DC92B30Q33894321-86D71DED-A696-45FD-B8C0-6F18F22F5B69Q34120517-7A0FC8D3-D4B7-4F1D-8803-72F54F963185Q34347386-EAE3D951-5D79-4D59-9E40-C64C6D1F476FQ34358206-2A7B2889-8AA8-48A0-8DFD-A1A389F295E2Q34537706-27752042-5045-46DE-BC0E-E2FFEEA0CE25Q34594726-F8D60370-0DC5-478B-950B-641E2AA8CE4BQ35042478-F0907758-6508-41D3-8BA7-B1C26BAB01C6Q35192199-A6991962-9C42-476E-8800-C9D526A0AC61Q35228349-5AA7CA32-DC9E-4BAE-B46A-41F06A8178DBQ35398012-1633D82A-0EB8-425B-B4DD-429787350C09Q35467763-FC6B636A-A433-4644-B592-0B04C3AFAF14Q35482140-1837929B-EF71-4679-9C3C-7FD12D3934E1Q35489205-073F69F4-6B09-42DD-99E3-104D399CC12FQ35490149-3A4B8B07-9F13-4DAB-878A-5754683F49E1Q35763835-FC3A92B2-28FB-4D4D-979B-63D5B98B6113Q35839114-025DF6C1-6F59-46CF-B5C1-13D7BE507274Q35849627-C84ADC49-7E0A-4BA2-9018-F3831ECD616CQ35851782-456BB3BE-BB47-4F22-85EE-2A6F074B5386Q35861268-FEA5B3FD-B0ED-48A4-BCB5-2C34981242BDQ35871026-30F92127-65C7-495D-A661-DE5D8417FCAFQ35877932-D07AB36E-D24A-4E97-9C53-57CA703DA9CBQ35880381-2CA639EC-CC1E-497B-A8EA-57F6D616DADDQ35898573-0C53AFC8-4025-40E7-81ED-E0A95D7CC234Q35953762-3097851C-21A6-4B35-BDAB-C9948654BEEB
P2860
Protection against vaginal SIV transmission with microencapsulated vaccine.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Protection against vaginal SIV transmission with microencapsulated vaccine.
@en
type
label
Protection against vaginal SIV transmission with microencapsulated vaccine.
@en
prefLabel
Protection against vaginal SIV transmission with microencapsulated vaccine.
@en
P2093
P356
P1433
P1476
Protection against vaginal SIV transmission with microencapsulated vaccine.
@en
P2093
Compans RW
Eldridge JH
Mulligan MJ
Yamshchikov GV
P304
P356
10.1126/SCIENCE.8493576
P407
P577
1993-05-01T00:00:00Z